Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Psychiatric genome-wide association study enrichment shows promise for future psychopharmaceutical discoveries

16 May 2025

Abstract excerpt

BACKGROUND: Innovation in psychiatric therapeutics has stagnated on known mechanisms. Psychiatric genome-wide association studies (GWAS) have identified hundreds of genome-wide significant (GWS) loci that have rapidly advanced our understanding of disease etiology. However, whether these results can be leveraged to improve clinical treatment for specific psychiatric disorders remains poorly understood. METHODS:...

Topics

Join the communities discussing this publication.

Genetic Associations and Epidemiology
Neurotransmitter Receptor Influence on Behavior
Schizophrenia research and treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40379965
DOI: 10.1038/s43856-025-00877-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Psychiatric genome-wide association study enrichment shows promise for future psychopharmaceutical discoveriesPMID 40379965Read ↗

Psychiatric Genome-wide Association Study Enrichment Shows Promise for Future Psychopharmaceutical DiscoveriesSemantic proximity Read ↗

Linking GWAS to pharmacological treatments for psychiatric disordersSemantic proximity Read ↗

Translating genome-wide association findings into new therapeutics for psychiatry.Semantic proximity Read ↗

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.Semantic proximity Read ↗

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and CompoundsSemantic proximity Read ↗

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.Semantic proximity Read ↗

Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.Semantic proximity Read ↗

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug ClassesSemantic proximity Read ↗

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.Semantic proximity Read ↗

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disordersSemantic proximity Read ↗

Genetically informed drug target prioritisation and repurposing for major depressive disorderSemantic proximity Read ↗

Genetic interactions between bioactive ingredients in traditional Chinese medicine and major depressive disorder, bipolar disorder, and schizophrenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.